Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes. / Kjaer, Laura Kofoed; Cejvanovic, Vanja; Henriksen, Trine; Hansen, Torben; Pedersen, Oluf; Christensen, Cramer Kjeldahl; Torp-Pedersen, Christian; Gerds, Thomas Alexander; Brandslund, Ivan; Mandrup-Poulsen, Thomas; Poulsen, Henrik Enghusen.
In: Free Radical Research, Vol. 53, No. 6, 03.06.2019, p. 694-703.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes
AU - Kjaer, Laura Kofoed
AU - Cejvanovic, Vanja
AU - Henriksen, Trine
AU - Hansen, Torben
AU - Pedersen, Oluf
AU - Christensen, Cramer Kjeldahl
AU - Torp-Pedersen, Christian
AU - Gerds, Thomas Alexander
AU - Brandslund, Ivan
AU - Mandrup-Poulsen, Thomas
AU - Poulsen, Henrik Enghusen
PY - 2019/6/3
Y1 - 2019/6/3
N2 - The relationship between RNA and DNA oxidation and pharmacological treatment has not been systematically investigated in patients with type 2 diabetes (T2D). We aimed to investigate the association between pharmacological treatments and levels of urinary markers of nucleic acid oxidation in T2D patients. Vejle Diabetes Biobank cohort data was nested into nationwide registry data. Multiple logistic regression was used to associate drug usage with risk of high (above median) RNA and DNA oxidation. Data from 2664 T2D patients (64% male, age range: 25-75) were included. Questionnaire-validated lipid lowering drug use was associated with low RNA oxidation (Odds ratio, OR 0.71, 95% CI: [0.59-0.87]). Insulin and non-specific antidiabetic drugs were associated with low DNA oxidation (insulin: OR 0.60, 95% CI [0.49-0.73]). Oral antidiabetics were associated with high DNA oxidation and RNA oxidation (OR 1.30, 95% CI [1.10-1.53] and OR 1.26, 95% CI [1.07-1.29]). Our findings indicate that diabetes-related drugs are associated with RNA and DNA oxidation and further studies are required to determine causality in T2D patients.
AB - The relationship between RNA and DNA oxidation and pharmacological treatment has not been systematically investigated in patients with type 2 diabetes (T2D). We aimed to investigate the association between pharmacological treatments and levels of urinary markers of nucleic acid oxidation in T2D patients. Vejle Diabetes Biobank cohort data was nested into nationwide registry data. Multiple logistic regression was used to associate drug usage with risk of high (above median) RNA and DNA oxidation. Data from 2664 T2D patients (64% male, age range: 25-75) were included. Questionnaire-validated lipid lowering drug use was associated with low RNA oxidation (Odds ratio, OR 0.71, 95% CI: [0.59-0.87]). Insulin and non-specific antidiabetic drugs were associated with low DNA oxidation (insulin: OR 0.60, 95% CI [0.49-0.73]). Oral antidiabetics were associated with high DNA oxidation and RNA oxidation (OR 1.30, 95% CI [1.10-1.53] and OR 1.26, 95% CI [1.07-1.29]). Our findings indicate that diabetes-related drugs are associated with RNA and DNA oxidation and further studies are required to determine causality in T2D patients.
KW - 8-Oxo-7
KW - 8-dihydro-2-deoxyguanosine
KW - 8-oxo-7
KW - 8-dihydroguanosine
KW - clinical pharmacology
KW - oxidative stress
KW - type 2 diabetes
U2 - 10.1080/10715762.2019.1622011
DO - 10.1080/10715762.2019.1622011
M3 - Journal article
C2 - 31161826
VL - 53
SP - 694
EP - 703
JO - Free Radical Research
JF - Free Radical Research
SN - 1071-5762
IS - 6
ER -
ID: 226001469